Total Payments
$4,909
2019 Payments
$1,325
Companies
3
Transactions
34
Medicare Patients
1,120
Medicare Billing
$112,598
Payment Breakdown by Category
Research$3,584 (73.0%)
Travel$1,050 (21.4%)
Food & Beverage$274.88 (5.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,584 | 24 | 73.0% |
| Travel and Lodging | $1,050 | 4 | 21.4% |
| Food and Beverage | $274.88 | 6 | 5.6% |
Payments by Type
Research
$3,584
24 transactions
General
$1,325
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $2,554 | 23 | $0 (2018) |
| Eisai Inc. | $1,325 | 10 | $0 (2019) |
| Eli Lilly and Company | $1,030 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $1,325 | 10 | Eisai Inc. ($1,325) |
| 2018 | $3,584 | 24 | Biogen, Inc. ($2,554) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $769.34 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $186.67 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $124.95 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $50.20 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $49.98 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $43.92 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| 06/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $78.00 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $56.69 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $55.08 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $50.47 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $37.17 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/21/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $336.49 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 06/21/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $134.92 | Research |
| Study: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | ||||||
| 05/23/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $43.99 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 05/23/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $40.15 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 05/23/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $39.97 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 05/23/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $29.30 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 05/23/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 05/23/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $23.88 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
| 05/22/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $114.00 | Research |
| Study: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $1,780 | 15 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,030 | 1 |
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Biogen, Inc. | $773.82 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 299 | 364 | $116,026 | $30,178 |
| 2022 | 7 | 338 | 451 | $129,927 | $35,815 |
| 2021 | 6 | 273 | 355 | $105,337 | $29,084 |
| 2020 | 6 | 210 | 307 | $71,427 | $17,522 |
Total Patients
1,120
Total Services
1,477
Medicare Billing
$112,598
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 73 | 97 | $36,685 | $10,179 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 78 | 99 | $30,618 | $7,008 | 22.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 40 | 40 | $17,871 | $5,433 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 49 | 57 | $15,120 | $2,552 | 16.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 24 | $7,872 | $2,510 | 31.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 17 | 17 | $6,292 | $1,745 | 27.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 18 | 30 | $1,568 | $751.22 | 47.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 79 | 99 | $36,963 | $10,969 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 62 | 62 | $27,376 | $8,577 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 76 | 87 | $26,361 | $6,459 | 24.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 56 | $9,408 | $3,013 | 32.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 57 | 68 | $17,680 | $2,903 | 16.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 23 | $7,337 | $2,457 | 33.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 26 | 56 | $4,802 | $1,436 | 29.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 87 | 118 | $44,014 | $13,292 | 30.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 72 | 89 | $26,916 | $6,737 | 25.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 52 | 61 | $15,860 | $2,850 | 18.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 25 | 25 | $7,705 | $2,570 | 33.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $6,477 | $2,436 | 37.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 20 | 45 | $4,365 | $1,200 | 27.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 87 | 130 | $33,909 | $7,094 | 20.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 59 | $9,617 | $3,564 | 37.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 32 | 32 | $9,728 | $3,332 | 34.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 21 | 21 | $6,363 | $2,002 | 31.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 11 | $3,975 | $1,028 | 25.9% |
About Dr. Jonathan Drake, M.D
Dr. Jonathan Drake, M.D is a Neurology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2013. The National Provider Identifier (NPI) number assigned to this provider is 1891132924.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Drake, M.D has received a total of $4,909 in payments from pharmaceutical and medical device companies, with $1,325 received in 2019. These payments were reported across 34 transactions from 3 companies. The most common payment nature is "" ($3,584).
As a Medicare-enrolled provider, Drake has provided services to 1,120 Medicare beneficiaries, totaling 1,477 services with total Medicare billing of $112,598. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Providence, RI
- Active Since 05/30/2013
- Last Updated 06/25/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891132924
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Providence
Syed Rizvi, Md, MD
Neurology — Payments: $482,996
Neurology $482,996
Stephen Salloway, Md, MD
Neurology — Payments: $323,920
Neurology $323,920
J Easton, Md, MD
Neurology — Payments: $274,886
Neurology $274,886
Jeffrey Wishik, Md, MD
Neurology — Payments: $46,542
Neurology $46,542
Dr. Karen Furie, Md, MD
Neurology — Payments: $31,250
Neurology $31,250
Dr. Chuang-Kuo Wu, M.d., Phd, M.D., PHD
Neurology — Payments: $27,531
Neurology $27,531